作者: Margaret R. Spitz , Rebecca H. Fueger , Xifeng Wu , Rodger Winn , Christopher I. Amos
DOI:
关键词: Risk factor 、 Randomized controlled trial 、 Clinical trial 、 Dose–response relationship 、 Ascorbic acid 、 Vitamin C 、 Clastogen 、 Medicine 、 Oncology 、 Internal medicine 、 Placebo
摘要: Mutagen sensitivity, as measured by an in vitro assay, has been described a risk factor for the development of several tobacco-related epithelial cancers. In studies have indicated that sensitivity to clastogenic effects bleomycin on chromosomes was reduced with introduction ascorbic acid dose-dependent relationship. We report results randomized clinical trial determine whether increasing levels oral could reduce mutagen sensitivity. For this study, we recruited 228 healthy smokers from 21 centers around country through Clinical Community Oncology Program. Each individual randomly assigned one four daily regimens: placebo, 1 g acid, 2 or 4 acid. Treatments were administered 16 weeks. Assessment made at baseline and weeks 4, 16, 20 (4 after cessation treatment). Serum 16. Demographic data collected each-measurement point. Analyses differences across treatment arms, well investigating correlation between serum level individuals. did not find dose-response relationship intake Additionally, association